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Atrial fi brillation (AF), the most common cardiac 
arrhythmia, is associated with substantial morbid-
ity and mortality due to the consequences of throm-
boembolic events. Framingham data suggest that pa-
tients with AF have a 1.5-2 fold increase in mortality 
rate when compared with the general population [1]. 
Th e overall objectives of treatment for AF include 
the prevention of complications, such as stroke, and 
maintaining the patient’s functional ability and qual-
ity of life. Since AF encourages structural, functional 
and electrophisiologic changes of the left atrium [2], 
understanding the treatments for AF is critical for 
achieving these important objectives. Treatment of 
AF is complex and depends on whether the patient 
is currently experiencing symptoms, how long the 
patient has been in AF, the overall health of the pa-
tient, co-morbidities, and the size and function of the 
heart’s chambers. General treatment options include 
pharmacological therapy, medical procedures, and 
lifestyle changes. Th e goals of treating AF include: 
preventing blood clots from forming, rhythm control, 
rate control and treating any underlying disorder caus-
ing or raising the risk of AF.
Rhythm control involves the restoration and main-
tenance of sinus rhythm. Th e benefi ts of sinus rhythm 
include decreasing symptoms, improved cardiac out-
put and exercise capacity, and reduced risk for stroke 
[3,4]. Th e choice of antiarrhythmic drugs depends on 
the type of AF, any other medical conditions, side ef-
fects of the medicine chosen and how well the AF 
responds.
Th e antiarrhythmic therapy proves highly effi  ca-
cious for some patients (< 50% of all patients). It is 
non-invasive but this approach is associated with high 
recurrence rate and adverse eff ects of the drugs. Sev-
eral drugs can convert the irregular heart rhythm back 
to a normal regular rhythm: quinidine, procainamide, 
disopyramide, acainide, propafenone, amiodarone, 
sotalol, ibutilide and dofetilide.
Rate control involves using medications to main-
tain a ventricular rate under 100 beats per minute 
without attempting to terminate the arrhythmia [5]. 
Drugs used to slow the heart rate include: digoxin, 
beta-blockers (propranolol and atenolol), calcium an-
tagonists, (diltiazem and verapamil), procainamide 
and quinidine. Beta-blockers and calcium channel 
blockers are fi rst-line agents for rate control in AF. 
Th ese drugs can be administered either intravenously 
or orally. Beta-blockers are especially eff ective in the 
presence of thyrotoxicosis and increased sympathetic 
tone or in patients with myocardial ischemia. Calci-
um channel blockers are more eff ective than digoxin 
when given orally for long-term rate control. Th ey re-
duce rate of AV nodal conduction and ventricular re-
sponse. Beta-blockers slow the sinus rate and decrease 
AV nodal conduction. Digoxin slows electrical con-
duction through the AV node and thus decreases the 
rate at which electrical impulses are conducted from 
the atria to the ventricles, and is often used to treat 
patients with heart failure. 
Rate control versus rhythm control. Clinical tri-
als such as AFFIRM, RACE and STAF [6,7,8] have 
compared a strategy of rate control versus rhythm 
control using antiarrhythmic drugs. All these trials 
reached the same conclusion: there is no mortality 
diff erence between the two approaches and that rate 
control may suffi  ce for most patients with AF. 
Cardioversion may be performed electively or 
emergently to restore sinus rhythm in patients with the 
new-onset AF. Cardioversion is most successful when 
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initiated within 7 days after the onset of AF. Th e need 
for cardioversion may be acute when AF is responsible 
for hypotension, heart failure or angina. Cardiover-
sion can be pharmacologic based or electrical. Sev-
eral antiarrhythmic drugs (fl ecainide, propafenone, 
dofetilide, amiodarone) have established effi  cacy in 
the pharmacologic conversion of AF to sinus rhythm. 
However, currently used drugs have limited effi  cacy 
and cause cardiac and extracardiac toxicity. 
 Anticoagulation. Before deciding the antico-
agulation therapy for individual patient with AF it 
is important to estimate the risk of stroke. An easy 
score to estimate the risk of stroke is the CHADS2 
score [congestive heart failure, hypertension, age >75 
(doubled), diabetes, stroke (doubled)]. In patients with 
CHADS2 score of >2 chronic anticoagulant therapy 
is recommended in a dose adjusted to achieve an INR 
value in the range of 2.0 to 3.0 unless contraindicat-
ed. Patients with CHADS2 score of 0 can be safely 
treated with aspirin. Th e decision in patients with 
CHADS2 scores 1 or 2 are individualized and depend 
on the other risk: vascular disease, age 65-74 and sex 
category (female). Th us, more detailed stroke risk fac-
tors for thromboembolism are indicated [9]. Warfarin 
reduces the risk of stroke in patients with AF but in-
creases the risk of hemorrhage and is diffi  cult to use. 
Dabigatran is a new oral direct thrombin inhibitor, 
and as compared with warfarin, given at a dose of 110 
mg, was associated with rates of stroke and systemic 
embolism similar to those with warfarin, but lower 
rate of major hemorrhage was observed [10]. 
Nonpharmacologic approaches. In some patients 
in whom AF cannot be adequately managed by phar-
macological therapy and if no underlying cause can be 
found the treatment options are several nonpharmaco-
logical approaches like atrioventricular node ablation 
with pacemaker placement, catheter-based ablation, 
and surgical ablation. In 1998, Haissaguerre et al. fi rst 
demonstrated that pulmonary veins (PVs) provided 
focal fi rings triggering the occurrence of paroxysmal 
AF [11]. Catheter ablation of the posterior left atrium, 
including the antra surrounding the PVs, has proven 
eff ective at ablating AF. Th ere are diff erent surgical 
ablative techniques that can eff ectively modify the 
atrial substrate: by making a series of atrial incisions 
and cryolesions. Th ese procedures results in the in-
terruption of the multiple reentry circuits necessary 
for the propagation of AF. Th e operation may be per-
formed alone or in conjunction with other cardiac sur-
gical procedures such as coronary artery bypass, atrial 
septal defect repair, congenital heart disease surgery 
or mitral valve repair [12]. 
In conclusion, understanding the diff erent treat-
ment options is vitally important for successful man-
agement of AF for further reducing cardiovascular 
morbidity and mortality.
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